uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

~ AMT-130 granted Breakthrough Therapy designation by FDA ~

~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generally well-tolerated, with no treatment-related serious adverse events ~

Read more at globenewswire.com